Coherus Oncology Inc (CHRS): Next-Year EPS Estimate 37.14%
As of 2026-06-04, Coherus Oncology Inc (CHRS) has a next-year EPS growth estimate of 37.14%.
On 2026-05-13, analyst consensus for CHRS's next-year EPS growth shifted from 36.59% to 37.14% — a positive change of 0.55 percentage points. The revised estimate has been sustained across 17 subsequent trading sessions. Current-year growth is projected at 34.94%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 37.14%
- EPS growth this year
- 34.94%
- EPS next quarter (est)
- -$0.24
- Last price
- $1.58
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 37.14% | 34.94% | -$0.24 | $1.58 |
| 2026-06-03 | 37.14% | 34.94% | -$0.24 | $1.47 |
| 2026-06-02 | 37.14% | 34.94% | -$0.24 | $1.52 |
| 2026-06-01 | 37.14% | 34.94% | -$0.24 | $1.57 |
| 2026-05-31 | 37.14% | 34.94% | -$0.24 | $1.59 |
| 2026-05-28 | 37.14% | 34.94% | -$0.24 | $1.65 |
| 2026-05-27 | 37.14% | 34.94% | -$0.24 | $1.66 |
| 2026-05-26 | 37.14% | 34.94% | -$0.24 | $1.64 |
| 2026-05-25 | 37.14% | 34.94% | -$0.24 | $1.61 |
| 2026-05-24 | 37.14% | 34.94% | -$0.24 | $1.61 |
| 2026-05-21 | 37.14% | 34.94% | -$0.24 | $1.57 |
| 2026-05-20 | 37.14% | 34.94% | -$0.24 | $1.51 |
| 2026-05-19 | 37.14% | 34.94% | -$0.24 | $1.48 |
| 2026-05-18 | 37.14% | 34.94% | -$0.24 | $1.49 |
| 2026-05-17 | 37.14% | 34.94% | -$0.24 | $1.57 |
| 2026-05-14 | 37.14% | 34.94% | -$0.24 | $1.63 |
| 2026-05-13 | 37.14% | 34.94% | -$0.24 | $1.74 |
| 2026-05-12 | 36.59% | 34.29% | -$0.24 | $1.71 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Coherus Oncology Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Coherus Oncology Inc (CHRS) has a next-year EPS growth estimate of 37.14%, based on analyst consensus.
When was the latest EPS estimate revision for CHRS?▾
The most recent revision occurred on 2026-05-13, when analysts adjusted the next-year EPS growth estimate from 36.59% to 37.14%.
What sector and industry does Coherus Oncology Inc belong to?▾
Coherus Oncology Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CHRS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Coherus Oncology Inc (CHRS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports